Trial Profile
An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Sapanisertib (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- 08 Jul 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2024.
- 08 Jul 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.
- 01 Jul 2022 Planned End Date changed from 30 Jun 2022 to 30 Jun 2023.